Association of race/ethnicity and insurance with survival in patients with diffuse large B‐cell lymphoma in a large real‐world cohort
Cancer Medicine · 2024
DOI: 10.1002/cam4.70032 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Yanling Jin und 5 weiteren Autor:innen. Beteiligte Einrichtung: F. Hoffmann-La Roche Ltd, Mississauga, Ontario, Canada. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
Few studies have evaluated disparities in race, ethnicity, and health insurance in real‐world health outcomes for patients with diffuse large B‐cell lymphoma (DLBCL). This study aimed to evaluate association between racial disparities and health insurance with real‐world health outcomes.
Methods
Patients with DLBCL (January 2011–July 2021) treated with first‐line therapy were selected from a real‐world database. Variables of interest included race/ethnicity, health insurance type (Medicaid, Commercial) by patient age (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- F. Hoffmann-La Roche Ltd, Mississauga, Ontario, Canada.
- Genentech, Inc., South San Francisco, California, USA.
Zitieren
APA
Jin, Y., Li, J., Mun, Y., Masaquel, A., Hu, S., & Biondo, J. M. L. (2024). Association of race/ethnicity and insurance with survival in patients with diffuse large B‐cell lymphoma in a large real‐world cohort. Cancer Medicine. https://doi.org/10.1002/cam4.70032
Vancouver
Jin Y, Li J, Mun Y, Masaquel A, Hu S, Biondo JML. Association of race/ethnicity and insurance with survival in patients with diffuse large B‐cell lymphoma in a large real‐world cohort. Cancer Medicine. 2024. doi:10.1002/cam4.70032
BibTeX
@article{Jin2024,
author = {Jin, Yanling and Li, Jia and Mun, Yong and Masaquel, Anthony and Hu, Sylvia and Biondo, Juliana M L},
title = {Association of race/ethnicity and insurance with survival in patients with diffuse large B‐cell lymphoma in a large real‐world cohort},
journal = {Cancer Medicine},
year = {2024},
doi = {10.1002/cam4.70032}
}
EUVIMED